Primary cilia are cellular surface projections enriched in receptors and signaling molecules, acting as signaling hubs that respond to stimuli. Malfunctions in primary cilia have been linked to human diseases, including retinopathies and ocular defects. Here, we focus on TMEM107, a protein localized to the transition zone of primary cilia. TMEM107 mutations were found in patients with Joubert and Meckel-Gruber syndromes. A mouse model lacking Tmem107 exhibited eye defects such as anophthalmia and microphthalmia, affecting retina differentiation. Tmem107 expression during prenatal mouse development correlated with phenotype occurrence, with enhanced expression in differentiating retina and optic stalk. TMEM107 deficiency in retinal organoids resulted in the loss of primary cilia, down-regulation of retina-specific genes, and cyst formation. Knocking out TMEM107 in human ARPE-19 cells prevented primary cilia formation and impaired response to Smoothened agonist treatment because of ectopic activation of the SHH pathway. Our data suggest TMEM107 plays a crucial role in early vertebrate eye development and ciliogenesis in the differentiating retina.
- MeSH
- lidé MeSH
- membránové proteiny genetika metabolismus MeSH
- myši MeSH
- polycystická choroba ledvin * genetika MeSH
- poruchy ciliární motility * genetika metabolismus MeSH
- retina metabolismus MeSH
- retinopathia pigmentosa * metabolismus MeSH
- těhotenství MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
N-terminal P23H opsin mutation accounts for most of retinitis pigmentosa (RP) cases. P23H functions and folding can be rescued by small chaperone ligands, which contributes to validate mutant opsin as a suitable target for pharmacological treatment of RP. However, the lack of structural details on P23H mutant opsin strongly impairs drug design, and new chemotypes of effective chaperones of P23H opsin are in high demand. Here, a computational-boosted workflow combining homology modeling with molecular dynamics (MD) simulations and virtual screening was used to select putative P23H opsin chaperones among different libraries through a structure-based approach. In vitro studies corroborated the reliability of the structural model generated in this work and identified a number of novel chemotypes of safe and effective chaperones able to promote P23H opsin trafficking to the outer cell membrane.
- MeSH
- lidé MeSH
- molekulární chaperony genetika metabolismus terapeutické užití MeSH
- opsiny * genetika MeSH
- reprodukovatelnost výsledků MeSH
- retinopathia pigmentosa * farmakoterapie genetika metabolismus MeSH
- tyčinkové opsiny chemie genetika metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Retinal degenerative diseases, such as age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy or glaucoma, represent the main causes of a decreased quality of vision or even blindness worldwide. However, despite considerable efforts, the treatment possibilities for these disorders remain very limited. A perspective is offered by cell therapy using mesenchymal stem cells (MSCs). These cells can be obtained from the bone marrow or adipose tissue of a particular patient, expanded in vitro and used as the autologous cells. MSCs possess potent immunoregulatory properties and can inhibit a harmful inflammatory reaction in the diseased retina. By the production of numerous growth and neurotrophic factors, they support the survival and growth of retinal cells. In addition, MSCs can protect retinal cells by antiapoptotic properties and could contribute to the regeneration of the diseased retina by their ability to differentiate into various cell types, including the cells of the retina. All of these properties indicate the potential of MSCs for the therapy of diseased retinas. This view is supported by the recent results of numerous experimental studies in different preclinical models. Here we provide an overview of the therapeutic properties of MSCs, and their use in experimental models of retinal diseases and in clinical trials.
- MeSH
- autologní transplantace MeSH
- buněčná a tkáňová terapie metody MeSH
- buněčná diferenciace MeSH
- buňky kostní dřeně cytologie metabolismus MeSH
- diabetická retinopatie genetika metabolismus patologie terapie MeSH
- glaukom genetika metabolismus patologie terapie MeSH
- klinické zkoušky jako téma MeSH
- lidé MeSH
- makulární degenerace genetika metabolismus patologie terapie MeSH
- mezenchymální kmenové buňky cytologie metabolismus MeSH
- mezibuněčné signální peptidy a proteiny genetika metabolismus MeSH
- modely nemocí na zvířatech MeSH
- neurotrofní faktory genetika metabolismus MeSH
- retina metabolismus patologie MeSH
- retinopathia pigmentosa genetika metabolismus patologie terapie MeSH
- transplantace mezenchymálních kmenových buněk metody MeSH
- tuková tkáň cytologie metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Hereditary retinal dystrophies, specifically retinitis pigmentosa (RP) are clinically and genetically heterogeneous diseases affecting primarily retinal cells and retinal pigment epithelial cells with blindness as a final outcome. Understanding the pathogenicity behind these diseases has been largely precluded by the unavailability of affected tissue from patients, large genetic heterogeneity and animal models that do not faithfully represent some human diseases. A landmark discovery of human induced pluripotent stem cells (hiPSCs) permitted the derivation of patient-specific cells. These cells have unlimited self-renewing capacity and the ability to differentiate into RP-affected cell types, allowing the studies of disease mechanism, drug discovery, and cell replacement therapies, both as individual cell types and organoid cultures. Together with precise genome editing, the patient specific hiPSC technology offers novel strategies for targeting the pathogenic mutations and design therapies toward retinal dystrophies. This study summarizes current hiPSC-based RP models and highlights key achievements and challenges of these cellular models, as well as questions that still remain unanswered. Stem Cells 2018;36:474-481.
- MeSH
- autologní štěp MeSH
- buněčná diferenciace * MeSH
- editace genu * MeSH
- genom lidský * MeSH
- indukované pluripotentní kmenové buňky metabolismus patologie MeSH
- lidé MeSH
- modely nemocí na zvířatech MeSH
- retinopathia pigmentosa * genetika metabolismus patologie terapie MeSH
- transplantace kmenových buněk * MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Splicing is catalyzed by the spliceosome, a complex of five major small nuclear ribonucleoprotein particles (snRNPs). The pre-mRNA splicing factor PRPF8 is a crucial component of the U5 snRNP, and together with EFTUD2 and SNRNP200, it forms a central module of the spliceosome. Using quantitative proteomics, we identified assembly intermediates containing PRPF8, EFTUD2, and SNRNP200 in association with the HSP90/R2TP complex, its ZNHIT2 cofactor, and additional proteins. HSP90 and R2TP bind unassembled U5 proteins in the cytoplasm, stabilize them, and promote the formation of the U5 snRNP. We further found that PRPF8 mutants causing Retinitis pigmentosa assemble less efficiently with the U5 snRNP and bind more strongly to R2TP, with one mutant retained in the cytoplasm in an R2TP-dependent manner. We propose that the HSP90/R2TP chaperone system promotes the assembly of a key module of U5 snRNP while assuring the quality control of PRPF8. The proteomics data further reveal new interactions between R2TP and the tuberous sclerosis complex (TSC), pointing to a potential link between growth signals and the assembly of key cellular machines.
- MeSH
- elongační faktory genetika metabolismus MeSH
- HeLa buňky MeSH
- interakční proteinové domény a motivy MeSH
- lidé MeSH
- malý jaderný ribonukleoprotein U1 metabolismus MeSH
- malý jaderný ribonukleoprotein U4-U6 metabolismus MeSH
- malý jaderný ribonukleoprotein U5 genetika metabolismus MeSH
- messenger RNA genetika metabolismus MeSH
- multiproteinové komplexy MeSH
- mutace MeSH
- prekurzory RNA genetika metabolismus MeSH
- proteiny tepelného šoku HSP90 metabolismus MeSH
- proteiny vázající RNA genetika metabolismus MeSH
- proteiny vázající vápník metabolismus MeSH
- proteomika metody MeSH
- retinopathia pigmentosa genetika metabolismus MeSH
- RNA interference MeSH
- sestřih RNA * MeSH
- stabilita proteinů MeSH
- transfekce MeSH
- vazba proteinů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The AD29 mutation in HPRP31 belongs to a series of mutations that were initially linked with the autosomal dominant disorder retinitis pigmentosa (RP) type 11. The HPRP31 gene encodes the hPrp31 protein that specifically associates with spliceosomal small nuclear ribonucleoprotein particles (snRNPs). Despite intensive research, it is still unclear how the AD29 (Ala216Pro) mutation causes RP. In this study, we report that the expression of this mutant protein affects cell proliferation and alters the structure of nuclear Cajal bodies that are connected with snRNP metabolism. Interestingly, these effects can be reversed by the over-expression of the hPrp6 protein, a binding partner of hPrp31. Although Ala216 is not contained within the U4 or U5 snRNP interacting domains, we present several lines of evidence that demonstrate that the association between the AD29 mutant and snRNPs in the cell nucleus is significantly reduced. Finally, we show that the stability of the AD29 mutant is severely affected resulting in its rapid degradation. Taken together, our results indicate that the Ala216Pro mutation destabilizes the hPrp31 protein structure in turn reducing its interaction with snRNP binding partners and leading to its rapid degradation. These findings significantly impact our understanding of the molecular mechanisms underlying RP and suggest that the insufficiency of the functional hPrp31 protein combined with the potential cytotoxicity associated with the expression the AD29 mutant are at least partially causative of the RP phenotype.
- MeSH
- Cajalova tělíska genetika metabolismus MeSH
- HeLa buňky MeSH
- lidé MeSH
- missense mutace MeSH
- oční proteiny genetika chemie metabolismus MeSH
- retinopathia pigmentosa genetika metabolismus MeSH
- ribonukleoproteiny malé jaderné genetika metabolismus MeSH
- spliceozomy genetika metabolismus MeSH
- stabilita proteinů MeSH
- vazba proteinů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH